DMK PHARMACEUTICALS CORP (DMK) Stock Overview
NASDAQ:DMK - US00547W3079 - Common Stock
DMK Key Statistics, Chart & Performance
The current stock price of DMK is 0.232 USD. In the past month the price decreased by -64.9%.
DMK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.36 | 693.28B | ||
| JNJ | JOHNSON & JOHNSON | 17.7 | 426.37B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.45 | 251.01B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18 | 247.76B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.28 | 244.60B | ||
| MRK | MERCK & CO. INC. | 10.93 | 210.16B | ||
| PFE | PFIZER INC | 7.29 | 140.60B | ||
| SNY | SANOFI-ADR | 11.16 | 120.63B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7 | 95.94B | ||
| GSK | GSK PLC-SPON ADR | 8.75 | 79.93B | ||
| ZTS | ZOETIS INC | 25.14 | 69.31B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.95 | 47.33B |
Related stock screener links
About DMK
Company Profile
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. The firm is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Company Info
DMK PHARMACEUTICALS CORP
11682 El Camino Real, Suite 300
San Diego CALIFORNIA US
Employees: 11
Phone: 18589972400
DMK PHARMACEUTICALS CORP / DMK FAQ
What is the stock price of DMK PHARMACEUTICALS CORP today?
The current stock price of DMK is 0.232 USD. The price increased by 0.91% in the last trading session.
What is the ticker symbol for DMK PHARMACEUTICALS CORP stock?
The exchange symbol of DMK PHARMACEUTICALS CORP is DMK and it is listed on the Nasdaq exchange.
On which exchange is DMK stock listed?
DMK stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for DMK PHARMACEUTICALS CORP stock?
5 analysts have analysed DMK and the average price target is 1.53 USD. This implies a price increase of 559.48% is expected in the next year compared to the current price of 0.232. Check the DMK PHARMACEUTICALS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is DMK PHARMACEUTICALS CORP worth?
DMK PHARMACEUTICALS CORP (DMK) has a market capitalization of 2.34M USD. This makes DMK a Nano Cap stock.
How many employees does DMK PHARMACEUTICALS CORP have?
DMK PHARMACEUTICALS CORP (DMK) currently has 11 employees.
Is DMK PHARMACEUTICALS CORP (DMK) expected to grow?
The Revenue of DMK PHARMACEUTICALS CORP (DMK) is expected to decline by -68.82% in the next year. Check the estimates tab for more information on the DMK EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy DMK PHARMACEUTICALS CORP (DMK) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of DMK, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of DMK, evaluating the profitability, health, valuation and growth aspects
- DMK PHARMACEUTICALS CORP (DMK) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- DMK PHARMACEUTICALS CORP (DMK) Sales and EPS estimates to see what analysts future expectations are.
- DMK PHARMACEUTICALS CORP (DMK) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- DMK PHARMACEUTICALS CORP (DMK) Insider and Institutional Ownership to learn about the owners and their transactions.
- DMK PHARMACEUTICALS CORP (DMK) Stock Chart to make your own analysis
- DMK PHARMACEUTICALS CORP (DMK) Latest news and press-releases to stay up to date.
Does DMK PHARMACEUTICALS CORP (DMK) stock pay dividends?
DMK does not pay a dividend.
When does DMK PHARMACEUTICALS CORP (DMK) report earnings?
DMK PHARMACEUTICALS CORP (DMK) will report earnings on 2024-03-14, before the market open.
What is the Price/Earnings (PE) ratio of DMK PHARMACEUTICALS CORP (DMK)?
DMK PHARMACEUTICALS CORP (DMK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.17).
DMK Technical Analysis
DMK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DMK. DMK may be in some trouble as it scores bad on both profitability and health.
DMK Financial Highlights
Over the last trailing twelve months DMK reported a non-GAAP Earnings per Share(EPS) of -9.17. The EPS increased by 37.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -248.15% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
DMK Forecast & Estimates
5 analysts have analysed DMK and the average price target is 1.53 USD. This implies a price increase of 559.48% is expected in the next year compared to the current price of 0.232.
For the next year, analysts expect an EPS growth of 64.16% and a revenue growth -68.82% for DMK